NIEMANN BRADLEY V.

SEC source: 0001209191-19-042104 · doc4.xml · nonDerivative · entry 4

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,970

SEC source: 0001209191-19-042104 · doc4.xml · nonDerivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,263

SEC source: 0001209191-19-042104 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,557

SEC source: 0001209191-19-042104 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,876

SEC source: 0001209191-19-041722 · doc4.xml · derivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,330 shares

Expires 2019-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On July 1, 2016, the reporting person was granted 6,660 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,330 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041722 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,239

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On July 1, 2016, the reporting person was granted 6,660 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,330 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-024379 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,909

SEC source: 0001209191-19-023382 · doc4.xml · derivative · entry 4

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,206

Underlying: Common Stock · 7,206 shares

Expires 2022-04-01

F4 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 1, 2019 to April 1, 2022. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 1, 2019, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-19-023382 · doc4.xml · derivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,939

Underlying: Common Stock · 11,939 shares

Expires 2029-04-01

F3 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-023382 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,157

F2 · shares: Represents time-based vesting restricted stock units that vest on the second anniversary of the grant date, April 1, 2019.

SEC source: 0001209191-19-023382 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,755

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2019.

SEC source: 0001209191-19-019145 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,152

SEC source: 0001209191-19-019145 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,061

SEC source: 0001209191-18-057416 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,361

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2017.

SEC source: 0001209191-18-057416 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,748

SEC source: 0001209191-18-041678 · doc4.xml · derivative · entry 7

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,250 shares

Expires 2023-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

SEC source: 0001209191-18-041678 · doc4.xml · derivative · entry 6

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2023-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 5

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,992

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.27 to $57.45, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 4

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,142

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.27 to $57.25, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,242

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.

SEC source: 0001209191-18-041678 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,992

F1 · kind: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 2, 2018.

SEC source: 0001209191-18-023291 · doc4.xml · derivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,055

Underlying: Common Stock · 5,055 shares

Expires 2021-04-02

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-18-023291 · doc4.xml · derivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,973

Underlying: Common Stock · 8,973 shares

Expires 2028-04-02

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-18-023291 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,296

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.

SEC source: 0001209191-17-065473 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,631

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.85 to $52.51, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-17-052626 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,178

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $49.81, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-17-044660 · doc4.xml · derivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,965

Underlying: Common Stock · 5,965 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-17-044660 · doc4.xml · derivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,409

Underlying: Common Stock · 10,409 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044660 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,134

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-16-148656 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,534

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, November 4, 2016.